Immunoblotting with the EGFR antibody showed that CMTM6 overexpression was associated with an overt increase in EGFR expression and the phosphorylation levels of EGFR and AKT, whereas CMTM6 knockdown led to a marked decrease in EGFR expression and the phosphorylation levels of EGFR and AKT in all of these NSCLC cells (Figure 2B), indicating that CMTM6 promotes the stability of EGFR and activation of downstream signaling in NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.